Author response

Headache

Volumn 51, Issue 6, 2011, Pages 1003-1005

  Dodick, David W ^a   Turkel, Catherine C ^b   Degryse, Ronald E ^b   Aurora, Sheena K ^c   Silberstein, Stephen D ^d   Lipton, Richard B ^e   Diener, Hans Christoph ^f   Brin, Mitchell F ^b,g  

^a MAYO CLINIC   (United States)

^b ALLERGAN INC   (United States)

^c SWEDISH MEDICAL CENTER   (United States)

^d THOMAS JEFFERSON UNIVERSITY   (United States)

^e ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^f UNIVERSITY OF DUISBURG ESSEN   (Germany)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMIGRAINE AGENT; ONABOTULINUMTOXIN A; UNCLASSIFIED DRUG;

ADVERSE OUTCOME; DATA ANALYSIS; DISEASE DURATION; DRUG ABUSE; HUMAN; INDEPENDENT VARIABLE; LETTER; MEDICAL DECISION MAKING; PREDICTOR VARIABLE; PRIORITY JOURNAL; PUBLICATION; STUDY DESIGN; TRANSFORMED MIGRAINE; TREATMENT OUTCOME;

EID: 79958155959     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/j.1526-4610.2011.01898_2.x     Document Type: Letter

References (4)

1. Dodick DW, Turkel CC, Degryse RE, et al,. OnabotulinumtoxinA for treatment of chronic migraine: Pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache. 2010; 50: 921-936.
2. Silberstein S, Tfelt-Hansen P, Dodick DW, et al,. Guidelines for controlled trials of prophylactic treatment of chronic migraine in adults. Cephalalgia. 2008; 28: 484-495. (Pubitemid 351502554)
3. Dworkin RH, Turk DC, McDermott MP, et al,. Interpreting the clinical importance of group differences in chronic pain clinical trials: IMMPACT recommendations. Pain. 2009; 146: 238-244.
4. Tfelt-Hansen P, Saxena PR, Dahlöf C, et al,. Ergotamine in the acute treatment of migraine: A review and European consensus. Brain. 2000; 123 (Pt 1): 9-18. (Pubitemid 30037964)